JP2019535250A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535250A5
JP2019535250A5 JP2019522745A JP2019522745A JP2019535250A5 JP 2019535250 A5 JP2019535250 A5 JP 2019535250A5 JP 2019522745 A JP2019522745 A JP 2019522745A JP 2019522745 A JP2019522745 A JP 2019522745A JP 2019535250 A5 JP2019535250 A5 JP 2019535250A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
hvr
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535250A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058880 external-priority patent/WO2018081648A2/en
Publication of JP2019535250A publication Critical patent/JP2019535250A/ja
Publication of JP2019535250A5 publication Critical patent/JP2019535250A5/ja
Pending legal-status Critical Current

Links

JP2019522745A 2016-10-29 2017-10-27 抗ｍｉｃ抗体及び使用方法 Pending JP2019535250A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662414670P 2016-10-29 2016-10-29
US62/414,670 2016-10-29
PCT/US2017/058880 WO2018081648A2 (en) 2016-10-29 2017-10-27 Anti-mic antibidies and methods of use

Publications (2)

Publication Number Publication Date
JP2019535250A JP2019535250A (ja) 2019-12-12
JP2019535250A5 true JP2019535250A5 (enExample) 2020-12-10

Family

ID=60409374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522745A Pending JP2019535250A (ja) 2016-10-29 2017-10-27 抗ｍｉｃ抗体及び使用方法

Country Status (5)

Country Link
US (1) US11555076B2 (enExample)
EP (1) EP3532091A2 (enExample)
JP (1) JP2019535250A (enExample)
CN (1) CN110267678A (enExample)
WO (1) WO2018081648A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
EP3830128A4 (en) * 2018-07-31 2022-08-17 Cullinan Mica Corp. ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B-SHEDDING AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
WO2020056045A1 (en) * 2018-09-13 2020-03-19 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
CN111217913B (zh) * 2018-11-26 2022-11-08 东莞市朋志生物科技有限公司 一种抗pg ii的抗体及其应用
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
EP4041406A4 (en) * 2019-10-09 2023-10-18 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR TREATING TUMORS WITH CYTOTOXIC T-CELL RESISTANCE
PH12022551009A1 (en) * 2019-10-31 2023-03-20 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
CN115836088A (zh) * 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN116547301A (zh) 2020-08-10 2023-08-04 先天制药公司 使用抗体进行的细胞表面mica和micb检测
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN115611976B (zh) * 2021-07-14 2024-05-14 浙江大学 一种人MICA/Bα3区水解相关的抗原表位肽及其应用
CN115611982B (zh) * 2021-07-14 2024-05-10 浙江大学 一种抗人MICA/Bα3区的单克隆抗体及其应用
US20250230246A1 (en) * 2021-10-27 2025-07-17 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
CN118027195B (zh) 2023-05-06 2025-07-04 合肥天港免疫药物有限公司 亲和力成熟的mica抗体及其应用
CN119569886A (zh) 2023-09-06 2025-03-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN120757638B (zh) * 2025-06-26 2026-04-10 安徽医科大学 一种anti-MAK16-IgG1单克隆亚型抗体及其制备方法和应用

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
HU216142B (hu) 1994-07-21 1999-04-28 Akzo Nobel N.V. Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2201484T3 (es) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
ES2524266T3 (es) 2008-07-08 2014-12-04 Incyte Corporation 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US9090690B2 (en) * 2009-06-18 2015-07-28 Pfizer Inc. Anti Notch-1 antibodies
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PT2760471T (pt) * 2011-09-30 2017-03-22 Dana Farber Cancer Inst Inc Péptidos terapêuticos
WO2013117647A1 (en) * 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
NZ629816A (en) * 2013-03-15 2017-07-28 Dana Farber Cancer Inst Inc Therapeutic peptides
US10851148B2 (en) * 2013-03-15 2020-12-01 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
CN106029694A (zh) * 2013-12-06 2016-10-12 达纳-法伯癌症研究院公司 治疗性肽
EP3270937A4 (en) * 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
BR112018068678A2 (pt) * 2016-03-15 2019-01-15 Innate Pharma anticorpos anti-mica
CA3093407A1 (en) * 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof

Similar Documents

Publication Publication Date Title
JP2024037894A5 (enExample)
JP2017514461A5 (enExample)
JP2021508469A5 (enExample)
JP2021533726A5 (enExample)
JP2019532619A5 (enExample)
JP2020510422A5 (enExample)
JP2021515565A5 (enExample)
JP2019513701A5 (enExample)
HRP20221083T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
JP2017149720A5 (enExample)
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2025092589A5 (enExample)
JP2021533796A5 (enExample)
JP2024016024A5 (enExample)
JP2023506465A5 (enExample)
IL276675B1 (en) Anti-pd-1 antibodies and uses thereof
JP2020502233A5 (enExample)
JP2020533965A5 (enExample)
JP2021511387A5 (enExample)
JP2021501575A5 (enExample)
JP2025513745A5 (enExample)
JP2020531003A5 (enExample)
JP2023533793A5 (enExample)
JP2019512210A5 (enExample)